I can't tolerate CPAP. What are my real options?

“I cannot tolerate CPAP” means three different things, and they get copied onto the wrong form. Medicare’s hypoglossal-nerve-stimulator rule (LCD L38310) counts intolerance as fewer than 4 hours a night, 5 nights a week, or the machine returned. Medicare’s PAP-device rule (LCD L33718) counts adherence as at least 4 hours on 70 percent of nights in a 30-day window during the first 90 days. Clinically, intolerance is broader: leak, pressure, claustrophobia, aerophagia, insomnia, a nose that will not cooperate. The menu after a real failure is an oral appliance, implanted stimulation (Inspire, and as of 8 August 2025 Nyxoah’s Genio), tirzepatide for a labeled OSA-with-obesity group, positional therapy in a positional phenotype, and weight change. None of those is a personality upgrade. Each has its own gate.

Why do three numbers keep getting mixed up?

L33718 is about whether the durable-medical supplier keeps getting paid for the PAP machine you already have. After the first three months, continued coverage needs a practitioner re-evaluation plus a download showing use of 4 or more hours per night on 70 percent of nights during a consecutive 30-day stretch inside that 90-day window. Fail the download and the payer can stop covering the device. That cutoff is a coverage rule. It is not a physiologic optimum, and it is not the definition used for implant packets.

L38310 is about whether Medicare will cover hypoglossal nerve stimulation. There, CPAP failure means AHI still greater than 15 despite using CPAP. CPAP intolerance means less than 4 hours per night, 5 nights per week, or the CPAP has been returned, plus shared decision-making after a sleep expert was involved. Four hours five nights a week is 20 hours a week. Four hours on 70 percent of nights is a different fraction. Copying one sentence into the other letter is how prior authorizations bounce.

Clinical intolerance has no AASM numeric cutoff. The 2019 PAP guideline spends its energy on education, troubleshooting, and follow-up, not on a stopwatch that equals “intolerant.” A person who uses 6 hours with a bleeding nasal bridge, or 3 hours 50 minutes and hates every minute, or who returned the device after a week of panic in a full-face mask, all have a problem. Only some of those problems match L38310. Only some match L33718’s continued-coverage test. Say which definition you are using before you say you “failed CPAP.”

Should you try to make CPAP work before you jump?

Often, yes. A wrong mask, an untreated leak, no humidity, unaddressed nasal obstruction, or an auto-range that is hunting all night can look like intolerance and still be fixable. The AASM 2019 PAP guideline gives a strong recommendation for educational interventions at the start, and conditional recommendations for behavioral troubleshooting and telemonitoring-guided help in the initial period. That is not “try harder” as a moral lecture. It is the evidence that a short, structured save attempt changes hours of use.

It is also not a life sentence. If the download is already under L38310’s intolerance line, or the device is in a closet, or you have given a serious mask-and-pressure effort and still cannot wear it, you are in the alternatives conversation. The practice’s CPAP alternatives page is a short triage list. This article is the definitions and the gates behind each item, which that hub page does not have room for.

Bring the download. Memory of “I used it most nights” is the error AASM quality measures have been citing for years: people overestimate use. A supplier letter that the unit was returned is gold for an implant file and useless if you still have the machine in a box at home.

Where does an oral appliance sit after CPAP intolerance?

The 2015 joint AASM/AADSM guideline’s STANDARD recommendation is the one that matches this situation: prescribe a custom, titratable oral appliance for adults with OSA who are intolerant of CPAP or prefer another therapy. CPAP still wins on AHI and oxygenation when both are used. The appliance is the alternative when CPAP is not being used. Repeat testing after the dentist titrates it is part of the same guideline, not an upsell.

Payers may still want a documented PAP trial. That is coverage sequencing, which is what the 2019 AADSM reimbursement papers argue about. It is not a reason to skip the physician diagnosis. Details of who is a dental candidate belong on the oral appliance article and page. The short version for this menu: if the teeth and jaw can accept a custom device, this is usually the first alternative to try that does not involve an operating room or a weekly injection.

What about Inspire?

Inspire is unilateral hypoglossal nerve stimulation with an implanted pulse generator. It is for a subset of people with moderate to severe obstructive disease who failed or did not tolerate PAP, after drug-induced sleep endoscopy has shown they do not have complete concentric collapse at the soft palate. Medicare’s LCD L38310 is stricter than FDA labeling on two numbers patients mix up constantly: Medicare wants AHI 15 to 65 and BMI under 35. FDA labeling from the 2023 expansion uses AHI 15 to 100 and a BMI warning up to 40. Commercial plans often track the FDA window, but that is plan-specific and not a promise about any Ohio contract.

Intolerance for this packet is the L38310 sentence, not the L33718 70 percent rule. If your download shows 4.2 hours on 80 percent of nights, you may be “adherent” for keeping the machine and still not “intolerant” for an implant. If you returned the device, you may meet intolerance without a pretty graph. Shared decision-making after a sleep consultation is in the LCD text. So is a PSG within 24 months of the first HGNS consult, predominantly obstructive events (central plus mixed under 25 percent of AHI), age 22 or older, and no anatomy that would compromise the implant (the LCD names tonsil size 3 or 4 as an example).

STAR-trial median AHI went from 29.3 to 9.0 at 12 months. That is a residual, not a cure. The Inspire therapy page is the criteria map. This paragraph is only to put Inspire on the post-CPAP menu with the correct intolerance definition attached.

What is Nyxoah Genio, and is it “the same as Inspire”?

No. On 8 August 2025 the FDA approved the Genio system (PMA P240024) for a subset of adults with moderate to severe OSA and AHI from 15 to 65. Nyxoah’s announcement and the AASM industry note describe bilateral hypoglossal stimulation, a leadless implant under the chin, and no implanted battery: an external wearable powers and controls it. DREAM-trial figures in that company announcement included a 63.5 percent AHI responder rate, a 71.3 percent ODI responder rate, a 70.8 percent median AHI reduction, and 82 percent of subjects reaching AHI under 15. Those are sponsor-reported pivotal results, not a head-to-head with Inspire in the same protocol.

Research summaries of the SSED also describe a labeled population that had failed, could not tolerate, or was ineligible for lifestyle modification, PAP, oral appliances, and pharmacotherapy such as tirzepatide. Confirm that wording against the live FDA IFU if you are making a surgical decision. Do not assume this practice implants Genio unless the physician has told you they do. The point of naming it here is that patients already search it, it is FDA-approved as of that August 2025 date, and it is a second device class in the same anatomic neighborhood, not a rebranded Inspire.

DISE still sits in the middle of this pathway for the trials that excluded complete concentric collapse. Skipping endoscopy because an ad showed a chin implant is how people get a surgery they cannot use.

Is Zepbound a CPAP replacement if you hate the mask?

No. Zepbound (tirzepatide) is indicated, in combination with a reduced-calorie diet and increased physical activity, to treat moderate to severe OSA in adults with obesity. SURMOUNT-OSA Study 5 enrolled people unable or unwilling to use PAP. Study 6 enrolled people on PAP. Mean AHI started near 50. Drug-arm AHI fell 25.3 and 29.3 events per hour. Remission or mild non-symptomatic OSA occurred in 42.2 percent and 50.2 percent. The USPI states the trials did not evaluate when or whether to stop PAP in people who had been using it.

If you cannot wear a mask, Study 5 is the closer cousin: a large AHI drop is possible, a cure is not the median outcome, and diet plus activity are on the label. If you can wear a mask some nights, adding a weight-loss medicine is not the same as throwing the machine away. Residual moderate disease after a 20 percent weight change is still disease. See the practice’s Zepbound page for the labeled indication. The dedicated weight article on this blog is the longer version of that math.

What about sleeping on your side, and what about weight without a shot?

Positional therapy is for the Cartwright phenotype: supine AHI at least twice the non-supine AHI, with a non-supine number that is actually safe. Tennis balls have miserable long-term use. Newer vibratory devices work in short studies; long-term adherence is the open question. If your side-sleeping AHI is already 25, a belt will not save you.

Weight loss without tirzepatide still lowers AHI in many people and still does not reliably erase moderate or severe OSA. It is a concurrent project, not a reason to go untreated for a year. Alcohol at night and untreated nasal obstruction sabotage every item on this list. They are not alternatives. They are leaks in the plan.

How do you pick from the menu without a brochure?

Match the tool to the physiology and to the definition of intolerance you actually meet. Custom oral appliance: OSA diagnosis, teeth that can take a device, CPAP not in use. Inspire: LCD or FDA numbers, DISE without complete concentric collapse, documented PAP failure or L38310 intolerance. Genio: FDA 2025 indication, different hardware, same need for a qualified implant pathway. Zepbound: obesity plus moderate to severe OSA, diet and activity, not a labeled PAP substitute. Positional: proven POSA. Weight: always relevant, rarely a solo cure for high AHI.

You do not have to pick in the parking lot. You do have to bring the CPAP download, the last sleep-study report, the BMI, and a sentence about whether the machine was returned. Call (614) 898-9340. If the problem is still a mask that can be fixed, that is allowed to be the answer. If it is not, the next device should be the one whose rules you actually fit, not the one with the most billboards.